Drug Profile


Alternative Names: 7-thia-8-oxoguanosine; 7T80G; ANA-245; ICN-10146; ICN25; Immunosine; Immusine; KN 25; N10146; N12143; N14316; NARI-10146; Thiaoxoguanosine

Latest Information Update: 21 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis; Valeant Pharmaceuticals International
  • Developer Anadys Pharmaceuticals
  • Class Antineoplastics; Antivirals; Immunotherapies; Purine nucleosides; Small molecules
  • Mechanism of Action Interferon alpha stimulants; Natural killer cell stimulants; Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Cancer; Hepatitis C

Most Recent Events

  • 04 Nov 2004 Data presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2004) have been added to the adverse events , and Viral Infections pharmacodynamics and therapeutic trials sections
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis
  • 01 Mar 2004 Phase-I/II clinical trials in Hepatitis C in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top